About Vanda Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.vandapharma.com/
Frequently Asked Questions
What is the 52-week range for VNDA?
The 52-week high is $9.94 and the 52-week low is $4.27.
What is the P/E ratio for VNDA?
The P/E ratio data is currently unavailable.
What is the dividend yield for VNDA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -84.95%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -127.41%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.59.
Analyst Recommendation Trends
Wall Street analyst consensus for VNDA over the last few months:
Latest VNDA News
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026.
Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It
Vanda Pharma is downgraded to Hold as revenue slips and HETLIOZ faces generics; BYSANTI launch nears but cash runway ends in 2027. Click for more on VNDA stock.
VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in delayed sleep-wake phase disorder (DSWPD).
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends to discuss these data with the U.S. Food and Drug Administration (FDA) and to submit a supplemental New Drug Application (sNDA) seeking approval of HETLIOZ® for DSWPD. If approved, HETLIOZ® would be the first FDA-approved medicine indicated for this condition.
Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10
Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-04 | McGuire Daniel Patrick | +80,000 | - | - |
| 2026-06-04 | Chrousos Phaedra | +41,600 | - | - |
| 2026-06-04 | Duncan Charles Cliff | +41,600 | - | - |
| 2026-06-04 | Ward Anne Sempowski | +41,600 | - | - |
| 2026-06-04 | Honore Tage | +41,600 | - | - |
| 2026-06-04 | Mitchell Stephen Ray | +41,600 | - | - |
| 2026-06-04 | DUGAN RICHARD W | +41,600 | - | - |
| 2026-05-18 | Mitchell Stephen Ray | -25,836 | - | - |
| 2026-04-22 | Duncan Charles Cliff | +57,101 | - | - |
| 2026-03-02 | Moran Kevin Patrick | -42,442 | $8.2659 | $350,821 |
| 2026-03-02 | Wijkstrom Joakim | -30,800 | $8.2659 | $254,590 |
| 2026-03-02 | Williams Timothy | -42,434 | $8.2659 | $350,755 |
| 2026-03-02 | Birznieks Gunther | -42,431 | $8.2659 | $350,730 |
| 2026-03-02 | Polymeropoulos Mihael Hristos | -156,235 | $8.1734 | $1,276,971 |
| 2026-02-23 | Honore Tage | -30,000 | $8.03 | $240,900 |
| 2026-02-18 | Wijkstrom Joakim | +125,000 | - | - |
| 2026-02-18 | Birznieks Gunther | +125,000 | - | - |
| 2026-02-18 | Williams Timothy | +125,000 | - | - |
| 2026-02-18 | Moran Kevin Patrick | +125,000 | - | - |
| 2026-02-18 | Polymeropoulos Mihael Hristos | +525,000 | - | - |